Terms: = Endocrine gland cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
2 results:
1. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract] [Full Text] [Related]
2. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract] [Full Text] [Related]
